Trio Pharmaceuticals
Triopharmaceuticals is pioneering the development of novel dual targeting antibody drugs to treat cancer by reducing toxicity and increasing immune response. Their innovative therapies, TIE-ADC™ and TRAILBody™, aim to precisely kill cancer cells, overcome tumor immunosuppression, and provide effective treatment with minimal toxicity. The company focuses on cancers such as AML, MDS, ovarian, endometrial, TNBC, and NSCLC, and is driven by a team of experienced entrepreneurs and scientists.
Industries
Nr. of Employees
small (1-50)
Trio Pharmaceuticals
930 Brittan Ave, San Carlos/San Francisco, CA
Products
Dual-action dual-targeting antibody therapeutics (including dual-targeting ADCs)
Therapeutic antibody platform designed to combine direct tumor cell killing with removal of immunosuppressive cells in the tumor microenvironment via dual target binding; includes development of antibody-drug conjugates using site-specific conjugation approaches.
Tumor-selective apoptosis-activating antibody therapeutics
Antibody-based therapeutics engineered to directly activate endogenous cell-death pathways in cancer cells while sparing normal cells; positioned for indications including AML/MDS, ovarian and endometrial cancers, triple-negative breast cancer, and non-small cell lung cancer.
Dual-action dual-targeting antibody therapeutics (including dual-targeting ADCs)
Therapeutic antibody platform designed to combine direct tumor cell killing with removal of immunosuppressive cells in the tumor microenvironment via dual target binding; includes development of antibody-drug conjugates using site-specific conjugation approaches.
Tumor-selective apoptosis-activating antibody therapeutics
Antibody-based therapeutics engineered to directly activate endogenous cell-death pathways in cancer cells while sparing normal cells; positioned for indications including AML/MDS, ovarian and endometrial cancers, triple-negative breast cancer, and non-small cell lung cancer.
Services
Short data-analysis training program advertised on the site.
Data analytics skills development program advertised on the site.
Program covering data-driven decision making advertised on the site.
Short data-analysis training program advertised on the site.
Data analytics skills development program advertised on the site.
Program covering data-driven decision making advertised on the site.
Expertise Areas
- Antibody therapeutic development
- Antibody-drug conjugate (ADC) development
- Death-receptor / TRAIL pathway therapeutics
- Oncology target selection and biomarker-driven discovery
Key Technologies
- Antibody engineering
- Antibody-drug conjugation (site-specific conjugation)
- Death-receptor (TRAIL) pathway agonist design
- Preclinical potency assays
News & Updates
Trio Pharmaceuticals collaborates with Ajinomoto Bio-Pharma Services to evaluate AJICAP™, a proprietary site-specific conjugation technology, for developing dual-action antibody drug conjugates.
Trio Pharmaceuticals announces the development of dual-functionality antibody-drug conjugates aimed at improving cancer treatment efficacy.
San Diego-based TRIO announced a successful oversubscribed seed funding round of $2.2 million, supported by local investors and Purdue University’s endowment fund.
Purdue Ventures invests $250,000 in TRIO Pharmaceuticals, a startup developing antibody-based cancer immunotherapeutics.
Trio Pharmaceuticals collaborates with Ajinomoto Bio-Pharma Services to evaluate AJICAP™, a proprietary site-specific conjugation technology, for developing dual-action antibody drug conjugates.
Trio Pharmaceuticals announces the development of dual-functionality antibody-drug conjugates aimed at improving cancer treatment efficacy.
San Diego-based TRIO announced a successful oversubscribed seed funding round of $2.2 million, supported by local investors and Purdue University’s endowment fund.
Purdue Ventures invests $250,000 in TRIO Pharmaceuticals, a startup developing antibody-based cancer immunotherapeutics.